A comparison of the effects of adrenaline and noradrenaline in critically ill patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN92846592

Enrollment

250

Registered

2005-03-07

Start date

2003-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory failure in critically ill patients Circulatory System

Interventions

Patients randomised to receive either adrenaline or noradrenaline

Eligibility

Inclusion criteria

Inclusion criteria: Critically ill patients requiring a catacholamine infusion for cardiovascular support

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Time to resolution of circulatory failure to pre-morbid state from commencement of catecholamine.	—

Secondary

Measure	Time frame
ICU length of stay and mortality, hospital mortality and 90-day mortality: degree of organ dysfunction during 28-day period (as determined by SOFA scores): cardiovascular, respiratory, renal, neurological, hepatic; and metabolic function.	—

Countries

Australia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026